The R+D+I Center, created in 2004 and located in Utebo (Zaragoza), is run by a group of highly qualified professionals who lead the development of products in the areas of Gastroenterology, Gynecology, Pediatrics, Urology, Cardiology and OTC products both nationally and internationally.
The Research Center is provided with a pilot plant, opened in 2010, operating under its own Quality System based on ICH Q8 and is certified in GM,P issued by the AEMPS (Spanish Agency of Medicines and Medical Devices), for the development of pharmaceutical and non-pharmaceutical products. This plant has also been authorized by the AEMPS for the manufacture, control, bottling and packaging of Medication for Clinical Trials (EU GMP Annex 13), with the possibility of producing Officinal Formulations and intermediate products.
Moreover, the Recordati Group maintains a constant investment for the development of treatments on cardiovascular diseases and particularly hypertension diseases. Thanks to these efforts, the Recordati Group has pioneered the discovery of substances like Lercanidipine, a calcium channel blocker of latest generation to relax blood vessels, which can reduce blood pressure.
Another of the great progresses made by the group has been Zanipress®/Zanitek®, a combination of both substances: lercanidipine and enalapril, new recommended drugs especially for the treatment of hypertension.
Currently, Recordati is committed to the development of drugs for the treatment of urinary disorders with innovative projects based on the development of new mechanisms of action and combination of marketed products that directly help improve bladder function.
We must also mention that with the acquisition of Orphan Europe, Recordati has increased its investments in the development of devices for the treatment of rare diseases.
verall, our facilities, our experience and our flexibility allow us to offer a comprehensive “contract manufacturing” service for the development of formulations from laboratory scale to industrial scale.
The pilot plant is complemented by an analytical area, prepared to support the technological and pharmaceutical activities.
Installations and technical means
Area of Pharmaceutical Technology
Laboratory of Pharmaceutical Technology
Area of solid forms.
Area of liquid and sem-isolid forms.
Area of Clinical Trial drugs preparation.
Area of secondary packaging of medicines used in clinical trials.
Area of purified water production and washing area.
Pharmaceutical Technology Equipment
Bohle Mixer – High Speed Mixer – Reactor/emulsifier – Capsule filler – Solid Dispenser – Liquid dispenser – Capsule counter – Dissolution Test (coupled with UV) – Disintegration Test – Water Activity Meter – Viscometers – Vacuum filter – Ultra-turrax and other stirring systems – Powder density and flow systems- laminar flow cabinet – Vacuum Sealer – Labeling Printer.
Physics and chemistry laboratory area.
Climatic Chamber Area.
HPLC and UHPLC with UV-Vis, IR and DAD detectors – Absorption and atomic emission Spectrophotometry – Gas Chromatography – IR spectrophotometry (FTIR) and UV-vis – Moisture Thermobalance – Automatic Titrator – KF Titrator – Osmometer – Rotary Evaporator …
The Pilot Plant has been authorized by the AEMPS for the development of the following pharmaceutical forms:
Liquids for external use (vaginal solutions and emultions).
Liquids for internal use (oral and rectal solutions).
Other solid forms (skin powders and oral solution powders).
Semi-solids (ointments, lotions and gels).
Hard gelatin capsules.
With the purpose of being a leader in innovation (technology, pharmaceutical forms, analysis …) we collaborate closely with research centers, universities, Spin-off, technology parks etc., which allows us to identify and develop products that meet the requirements of our customers and consumers by providing products with high added value.
In this respect, we highlight the design and development of a full range of Oral Rehydration Solutions (ORS + Lactobacillus reuteri) Intestinal evacuants (present in over 30 countries), Laxatives (PEG without electrolytes) and Regulators of intestinal transit (fermentable and non-fermentable fiber) among others.
The increasing activity at the R+D+I center, has allowed, from its creation to the present, the marketing of numerous products.